Institutes
Refine
Year of publication
Document Type
- Article (1820)
- Doctoral Thesis (444)
- Preprint (158)
- Conference Proceeding (108)
- Review (32)
- Book (17)
- Part of Periodical (12)
- Contribution to a Periodical (9)
- Part of a Book (7)
- Report (3)
Is part of the Bibliography
- no (2612)
Keywords
- COVID-19 (45)
- SARS-CoV-2 (37)
- inflammation (32)
- Epilepsy (19)
- Video (19)
- Inflammation (17)
- prostate cancer (17)
- ADHD (13)
- Cancer (12)
- autophagy (12)
Institute
- Medizin (2612)
- Biowissenschaften (32)
- Biochemie und Chemie (30)
- Biochemie, Chemie und Pharmazie (29)
- Georg-Speyer-Haus (25)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (19)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (19)
- Präsidium (17)
- Frankfurt Institute for Advanced Studies (FIAS) (16)
- Ernst Strüngmann Institut (12)
Background: Trauma-related guilt and shame are crucial for the development and maintenance of PTSD (posttraumatic stress disorder). We developed an intervention combining cognitive techniques with loving-kindness meditations (C-METTA) that specifically target these emotions. C-METTA is an intervention of six weekly individual treatment sessions followed by a four-week practice phase.
Objective: This study examined C-METTA in a proof-of-concept study within a randomized wait-list controlled trial.
Method: We randomly assigned 32 trauma-exposed patients with a DSM-5 diagnosis to C-METTA or a wait-list condition (WL). Primary outcomes were clinician-rated PTSD symptoms (CAPS-5) and trauma-related guilt and shame. Secondary outcomes included psychopathology, self-criticism, well-being, and self-compassion. Outcomes were assessed before the intervention phase and after the practice phase.
Results: Mixed-design analyses showed greater reductions in C-METTA versus WL in clinician-rated PTSD symptoms (d = −1.09), guilt (d = −2.85), shame (d = −2.14), psychopathology and self-criticism.
Conclusion: Our findings support positive outcomes of C-METTA and might contribute to improved care for patients with stress-related disorders. The study was registered in the German Clinical Trials Register (DRKS00023470).
HIGHLIGHTS
C-METTA is an intervention that addresses trauma-related guilt and shame and combines cognitive interventions with loving-kindness meditations.
A proof-of-concept study was conducted examining C-METTA in a wait-list randomized controlled trial
C-METTA led to reductions in trauma-related guilt and shame and PTSD symptoms.
Background: Despite known clinical benefits, guideline-recommended heart rate (HR) control is not achieved for a significant proportion of patients with HF with reduced ejection fraction. The wearable cardioverter-defibrillator (WCD) provides continuous HR monitoring and alerts that could aid medication titration.
Objective: This study sought to evaluate sex differences in achieving guideline-recommended HR control during a period of WCD use.
Methods: Data from patients fitted with a WCD from 2015 to 2018 were obtained from the manufacturer’s database (ZOLL). The proportion of patients with adequate nighttime resting HR control at the beginning of use (BOU) and at the end of use (EOU) were compared by sex. Adequate HR control was defined as having a nighttime median HR <70 beats/min.
Results: A total of 21,440 women and a comparative sample of 17,328 men (median 90 [IQR 59–116] days of WCD wear) were included in the final dataset. Among patients who did not receive a shock, over half had insufficient HR control at BOU (59% of women, 53% of men). Although the proportion of patients with resting HR ≥70 beats/min improved by EOU, 43% of women and 36% of men did not achieve guideline-recommended HR control.
Conclusion: A significant proportion of women and men did not achieve adequate HR control during a period of medical therapy optimization. Compared with men, a greater proportion of women receiving WCD shocks had insufficiently controlled HR in the week preceding ventricular tachyarrhythmia/ventricular fibrillation and 43% of nonshocked women, compared with 36% of men, did not reach adequate HR control during the study period. The WCD can be utilized as a remote monitoring tool to record HR and inform adequate uptitration of beta-blockers, with particular focus on reducing the treatment gap in women.
Evidence-based and comprehensible health information is a key element of evidence-based medicine and public health. The goal is informed decision-making based on realistic estimations of health risks and accurate expectations about benefits and harms of interventions. In Germany, standards of evidence-based risk information were poorly followed during the COVID-19 pandemic. Frequently, public information was biased, fragmentary and misleading. Pandemic-related threat scenarios induced emotional distress and unnecessary anxiety. A systematic and comprehensive evaluation of the pandemic measures is crucial, but still pending in Germany. A critical analysis of risk communication by experts, politicians and the media during the pandemic should be a key element of the evaluation process. Evaluation of decision making and media reporting during the pandemic should improve preparedness for future crises.
The ICH M13A draft bioequivalence guideline allows the exclusion of very low plasma profiles from the statistical evaluation in exceptional cases, i.e., if such phenomenon occurs due to non-compliance of subjects (not swallowing the product). Moreover, the draft ICH guideline requests additional bioequivalence studies for medicinal products with pH-dependent solubility after concomitant administration of gastric pH modifying preparations, e.g., proton pump inhibitors. Both regulations are scientifically sound, however, would need further specification. Main problem in this context is that compounds with very low solubility and slow intrinsic dissolution in the intestinal environment will cause significant bioavailability problems if their solid oral dosage forms are emptied from the stomach undisintegrated. Also very low plasma profiles may result under these circumstances. Such cases can occur accidentally and are not resultant of non-compliance. Thus, limitation for one case per study only as suggested in the guideline is not justified.
Therapierefraktärer Schmerz ist ein weit verbreitetes, äußerst belastendes Leitsymptom rheumatischer Erkrankungen. Viele Betroffene weichen daher bei Versagen der Standardmedikation selbstständig auf Cannabis oder die strukturell verwandte Substanz Palmitoylethanolamid (PEA) als Add-On- oder Alternativtherapie aus, obwohl dies in Deutschland bisher nur eingeschränkt zulässig ist. Die deutsche Gesetzgebung ist diesbezüglich nicht eindeutig, weshalb Ärzt:innen in ihrer Entscheidung, Cannabis zu verschreiben, auf Leitlinien, Fallberichte und Expert:innenmeinungen zurückgreifen müssen. Dies führt zu schwierigen Einzelfallentscheidungen, da sich die derzeitige Datenlage zu Cannabis-based Medicine (CBM) bzw. PEA und Rheuma als mangelhaft darstellt und die Leitlinien dementsprechend keine klaren Empfehlungen enthalten. Ziel der vorliegenden Arbeit ist es, die vorhandene Evidenz zusammenzufassen, zu ordnen und anhand der Hill-Kriterien den möglichen kausalen Zusammenhang zwischen der Einnahme von CBM bzw. PEA und der analgetischen Wirkung bei Rheumaschmerzen zu prüfen.
Lifestyle factors—such as diet, physical activity (PA), smoking, and alcohol consumption—have a significant impact on mortality as well as healthcare costs. Moreover, they play a crucial role in the development of type 2 diabetes mellitus (DM2). There also seems to be a link between lifestyle behaviours and insulin resistance, which is often a precursor of DM2. This study uses an enhanced Healthy Living Index (HLI) integrating accelerometric data and an Ecological Momentary Assessment (EMA) to explore differences in lifestyle between insulin-sensitive (IS) and insulin-resistant (IR) individuals. Moreover, it explores the association between lifestyle behaviours and inflammation. Analysing data from 99 participants of the mPRIME study (57 women and 42 men; mean age 49.8 years), we calculated HLI scores—ranging from 0 to 4— based on adherence to specific low-risk lifestyle behaviours, including non-smoking, adhering to a healthy diet, maximally moderate alcohol consumption, and meeting World Health Organization (WHO) PA guidelines. Insulin sensitivity was assessed using a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and C-reactive protein (CRP) levels were used as a proxy for inflammation. Lifestyle behaviours, represented by HLI scores, were significantly different between IS and IR individuals (U = 1529.0; p = 0.023). The difference in the HLI score between IR and IS individuals was mainly driven by lower adherence to PA recommendations in the IR group. Moreover, reduced PA was linked to increased CRP levels in the IR group (r = −0.368, p = 0.014). Our findings suggest that enhancing PA, especially among individuals with impaired insulin resistance, holds significant promise as a preventive strategy.
MicroRNAs (miRNAs) are critical post-transcriptional regulators in many biological processes. They act by guiding RNA-induced silencing complexes to miRNA response elements (MREs) in target mRNAs, inducing translational inhibition and/or mRNA degradation. Functional MREs are expected to predominantly occur in the 3’ untranslated region and involve perfect base-pairing of the miRNA seed. Here, we generate a high-resolution map of miR-181a/b-1 (miR-181) MREs to define the targeting rules of miR-181 in developing murine T-cells. By combining a multi-omics approach with computational high-resolution analyses, we uncover novel miR-181 targets and demonstrate that miR-181 acts predominantly through RNA destabilization. Importantly, we discover an alternative seed match and identify a distinct set of targets with repeat elements in the coding sequence which are targeted by miR-181 and mediate translational inhibition. In conclusion, deep profiling of MREs in primary cells is critical to expand physiologically relevant targetomes and establish context-dependent miRNA targeting rules.
Key Points:
* Deep profiling identifies novel targets of miR-181 associated with global gene regulation.
* miR-181 MREs in repeat elements in the coding sequence act through translational inhibition.
* High-resolution analysis reveals an alternative seed match in functional MREs.
Inflammation is a regulated reaction of the body to control a threat such as infection or injury. An efficient resolution of inflammation is critical to prevent the development of chronic inflammation and to restore tissue homeostasis. Macrophages (Mf) play a crucial role in the onset, but also in the resolution of inflammation, because they phagocytose and eliminate pathogens and tissue debris. Efficient efferocytosis, i.e. the engulfment of apoptotic cells, represents an important trigger for the onset of the resolution response and contributes to the pro-resolving reprogramming of Mf. Despite the importance of post- transcriptional modes of regulation during the resolution phase and translational control as a key node modulating gene expression in immune cells, relevant translational alterations remain largely elusive.
In the present study, I aimed to identify translationally regulated targets in inflammatory primary murine Mf upon resolution-promoting efferocytosis. To this end, I used total RNA-sequencing as well as de novo proteomics analyses to determine global transcriptional and translational changes. Sequencing data confirmed that efferocytosis induced a pro-resolution signature in inflammatory Mf and pointed towards translational regulation because the related integrated stress response was enriched upon efferocytosis. While changes of gene expression between efferocytic and non-efferocytic Mf appeared rather small at the transcriptional level, I observed considerable differences at the level of de novo synthesized proteins. This finding suggests a regulation at the level of translation. Furthermore, the tight connection between translational and metabolic changes was confirmed by enriched metabolism-associated terms of targets upregulated by efferocytosis at both RNA and de novo protein level. Interestingly, analysis of translationally regulated targets in response to inflammatory stimulation showed reduced translation for most targets, with only little impact of efferocytosis. Among those targets, I identified pro-resolving matrix metallopeptidase 12 (Mmp12) as a novel candidate, which showed translational repression during early inflammation and translational increase during the resolution phase. Noteworthy, a first indicator for a potential translation regulatory component of Mmp12 were the extremely high mRNA levels and not overly high de novo protein levels. Validation experiments recapitulated a slight elevation of Mmp12 mRNA expression and a significant downregulation of MMP12 intracellular protein levels in inflammatory Mf, as observed in the RNA-seq and de novo proteomics datasets. To investigate whether the discrepancy in mRNA and protein expression were due to changes in translation, I applied polysomal fractionation analysis to determine the translational status of Mmp12. Inflammatory Mf displayed a significantly lower relative Mmp12 mRNA abundance in the late polysomes compared to naïve Mf, suggesting reduced translational efficiency upon inflammatory stimulation. Consequently, extracellular MMP12 levels in the supernatant of inflammatory Mf decreased, although with a slight delay.
The functional impact of attenuated Mmp12 translation upon inflammatory stimulation was assessed in migration assays. While siRNA-mediated knockdown of Mmp12 did not alter Mf migration on uncoated plates, it increased migration 3-fold on matrigel/elastin-coated plates. Importantly, the increase in migrated distance driven by siMmp12 could be lowered by the addition of exogenous recombinant MMP12 protein. In line with reduced Mmp12 translation and MMP12 protein in inflammatory Mf, I observed a significant increase in cell migration on matrigel/elastin-coated plates, while it remained unaltered on uncoated plates. Consequently, Mf elastase MMP12 degrades elastin, thereby cell migration along elastin fibers is diminished. In inflammatory Mf, Mmp12 is translationally downregulated, thereby enhancing the migratory capacity.
In summary, the present study identifies a substantial contribution of translational regulation in the course of inflammation shown by high changes between inflammatory naïve and efferocytic Mf at the de novo proteomic level. Specifically, I was able to determine the translational regulation of pro-resolving Mmp12, which is repressed during early inflammation and recovers during the resolution phase. Functionally, translational control of MMP12 emerged as a strategy to alter the migratory properties of Mf, enabling enhanced, matrix- dependent migration of Mf during the early inflammatory phase, while restricting migration during the resolution phase.
The human immune system is determined by the functionality of the human lymph node. With the use of high-throughput techniques in clinical diagnostics, a large number of data is currently collected. The new data on the spatiotemporal organization of cells offers new possibilities to build a mathematical model of the human lymph node - a virtual lymph node. The virtual lymph node can be applied to simulate drug responses and may be used in clinical diagnosis. Here, we review mathematical models of the human lymph node from the viewpoint of cellular processes. Starting with classical methods, such as systems of differential equations, we discuss the values of different levels of abstraction and methods in the range from artificial intelligence techniques formalism.
Highlights
• Single nucleotide variants (SNVs) may affect transcription factor (TF) binding
• Fast statistical approach to assess significance of differential TF binding for SNVs
• Validate new approach on in vitro and in vivo TF binding assays
• Applications on GWAS SNVs and large eQTL studies illustrate utility
Summary
Non-coding variants located within regulatory elements may alter gene expression by modifying transcription factor (TF) binding sites, thereby leading to functional consequences. Different TF models are being used to assess the effect of DNA sequence variants, such as single nucleotide variants (SNVs). Often existing methods are slow and do not assess statistical significance of results. We investigated the distribution of absolute maximal differential TF binding scores for general computational models that affect TF binding. We find that a modified Laplace distribution can adequately approximate the empirical distributions. A benchmark on in vitro and in vivo datasets showed that our approach improves upon an existing method in terms of performance and speed. Applications on eQTLs and on a genome-wide association study illustrate the usefulness of our statistics by highlighting cell type-specific regulators and target genes. An implementation of our approach is freely available on GitHub and as bioconda package.
Background: Novel treatments are needed to control refractory status epilepticus (SE). This study aimed to assess the potential effectiveness of fenfluramine (FFA) as an acute treatment option for SE. We present a summary of clinical cases where oral FFA was used in SE.
Methods: A case of an adult patient with Lennox–Gastaut syndrome (LGS) who was treated with FFA due to refractory SE is presented in detail. To identify studies that evaluated the use of FFA in SE, we performed a systematic literature search.
Results: Four case reports on the acute treatment with FFA of SE in children and adults with Dravet syndrome (DS) and LGS were available. We report in detail a 30-year-old woman with LGS of structural etiology, who presented with generalized tonic and dialeptic seizures manifesting at high frequencies without a return to clinical baseline constituting the diagnosis of SE. Treatment with anti-seizure medications up to lacosamide 600 mg/d, brivaracetam 300 mg/d, valproate 1,600 mg/d, and various benzodiazepines did not resolve the SE. Due to ongoing refractory SE and following an unremarkable echocardiography, treatment was initiated with FFA, with an initial dose of 10 mg/d (0.22 mg/kg body weight [bw]) and fast up-titration to 26 mg/d (0.58 mg/kg bw) within 10 days. Subsequently, the patient experienced a resolution of SE within 4 days, accompanied by a notable improvement in clinical presentation and regaining her mobility, walking with the assistance of physiotherapists. In the three cases reported in the literature, DS patients with SE were treated with FFA, and a cessation of SE was observed within a few days. No treatment-emergent adverse events were observed during FFA treatment in any of the four cases.
Conclusions: Based on the reported cases, FFA might be a promising option for the acute treatment of SE in patients with DS and LGS. Observational data show a decreased SE frequency while on FFA, suggesting a potentially preventive role of FFA in these populations.
Key points
* We summarize four cases of refractory status epilepticus (SE) successfully treated with fenfluramine.
* Refractory SE resolved after 4–7 days on fenfluramine.
* Swift fenfluramine up-titration was well-tolerated during SE treatment.
* Treatment-emergent adverse events on fenfluramine were not observed.
* Fenfluramine might be a valuable acute treatment option for SE in Dravet and Lennox–Gastaut syndromes.
Tight control over transcription factor activity is necessary for a sensible balance between cellular proliferation and differentiation in the embryo and during tissue homeostasis by adult stem cells, but mechanistic details have remained incomplete. The homeodomain transcription factor MEIS2 is an important regulator of neurogenesis in the ventricular–subventricular zone (V-SVZ) adult stem cell niche in mice. We here identify MEIS2 as direct target of the intracellular protease calpain-2 (composed of the catalytic subunit CAPN2 and the regulatory subunit CAPNS1). Phosphorylation at conserved serine and/or threonine residues, or dimerization with PBX1, reduced the sensitivity of MEIS2 towards cleavage by calpain-2. In the adult V-SVZ, calpain-2 activity is high in stem and progenitor cells, but rapidly declines during neuronal differentiation, which is accompanied by increased stability of MEIS2 full-length protein. In accordance with this, blocking calpain-2 activity in stem and progenitor cells, or overexpression of a cleavage-insensitive form of MEIS2, increased the production of neurons, whereas overexpression of a catalytically active CAPN2 reduced it. Collectively, our results support a key role for calpain-2 in controlling the output of adult V-SVZ neural stem and progenitor cells through cleavage of the neuronal fate determinant MEIS2.
Highlights
• Reduced evoked theta activity in the deaf.
• Reduced theta-gamma and alpha-gamma cross-frequency couplings in the deaf.
• Stronger delta-alpha coupling in the deaf.
Abstract
Neurons within a neuronal network can be grouped by bottom-up and top-down influences using synchrony in neuronal oscillations. This creates the representation of perceptual objects from sensory features. Oscillatory activity can be differentiated into stimulus-phase-locked (evoked) and non-phase-locked (induced). The former is mainly determined by sensory input, the latter by higher-level (cortical) processing. Effects of auditory deprivation on cortical oscillations have been studied in congenitally deaf cats (CDCs) using cochlear implant (CI) stimulation. CI-induced alpha, beta, and gamma activity were compromised in the auditory cortex of CDCs. Furthermore, top-down information flow between secondary and primary auditory areas in hearing cats, conveyed by induced alpha oscillations, was lost in CDCs. Here we used the matching pursuit algorithm to assess components of such oscillatory activity in local field potentials recorded in primary field A1. Additionally to the loss of induced alpha oscillations, we also found a loss of evoked theta activity in CDCs. The loss of theta and alpha activity in CDCs can be directly related to reduced high-frequency (gamma-band) activity due to cross-frequency coupling. Here we quantified such cross-frequency coupling in adult 1) hearing-experienced, acoustically stimulated cats (aHCs), 2) hearing-experienced cats following acute pharmacological deafening and subsequent CIs, thus in electrically stimulated cats (eHCs), and 3) electrically stimulated CDCs. We found significant cross-frequency coupling in all animal groups in > 70% of auditory-responsive sites. The predominant coupling in aHCs and eHCs was between theta/alpha phase and gamma power. In CDCs such coupling was lost and replaced by alpha oscillations coupling to delta/theta phase. Thus, alpha/theta oscillations synchronize high-frequency gamma activity only in hearing-experienced cats. The absence of induced alpha and theta oscillations contributes to the loss of induced gamma power in CDCs, thereby signifying impaired local network activity.
Diese Arbeit hatte das Ziel, die Größe einer DVT-Aufnahme (FOV) mit der Größe der durch die Indikationsstellung definierten Region (ROI) zu vergleichen. Durch eine speziell dafür entwickelte Software sollten Messungen in den Datensätzen ermöglicht werden. Die dazu verwendeten 332 Datensätze wurden zufallsverteilt aus den mit einem Orthophos SL-3D DVT-Gerät der Firma Dentsply Sirona in der Poliklinik für zahnärztliche Chirurgie und Implantologie des ZZMK (Carolinum) in Frankfurt angefertigten Röntgenaufnahmen selektiert.
Es wurde die Auswertungssoftware ExRoi entwickelt, mit der die Werte des axialen Durchmessers, die Höhe (vertikale Dimension) sowie die Distanz der Mittelpunkte von FOV und ROI direkt in den Datensätzen bestimmt werden konnten. Zusätzlich wurde festgehalten, welche rechtfertigenden Indikationen gestellt und welche Auflösungsmodi verwendet wurden.
Die Stichprobe bestand aus Aufnahmen mit einem axialen Durchmesser von 8 cm [VOL 1] (n= 76, entsprechend 46,39%), 5 cm Durchmesser [VOL 2] (n = 102, entsprechend 30,72%) und 11 cm Durchmesser [VOL 3] (n= 154, entsprechend 22,89%). 95,18% der Aufnahmen wurden im HD-Modus mit laut Herstellerangaben vier Mal so vielen Aufnahmen im Vergleich zum SD-Modus angefertigt. Hauptindikationen waren Implantat Planung (45,1%) und Planungen komplizierter Zahn-Extraktionen (25,5%).
Die Messungen zum Vergleich des axialen Durchmessers zeigten, dass bei Verwendung des VOL 2 die ROI im Mittel den größten Anteil der FOV nutzt (78,52 %), den kleinsten Anteil nutzt durchschnittlich VOL 1 (56,04 %). Dazwischen liegt VOL 3 (69,12 %). In der Vertikalen nutzt die ROI von VOL 3 mittelwertig den größten Anteil der FOV (81,87 %), den kleinsten Mittelwert hat VOL 1 (58,76 %). VOL 2 liegt zwischen diesen Werten (64,47 %).
In allen Fällen war das FOV größer als die ROI und die ROI lag im Bereich des gewählten FOV.
Die Mittelpunkte von FOV und ROI lagen im Mittel in der axialen Ebene in Abhängigkeit vom gewählten Volumen um rund 9-13 mm auseinander, in der coronalen und sagittalen Ebene um rund 5-6mm.
Aus diesen Ergebnissen kann für das verwendete Gerät eine gute Trefferquote für die ROI abgeleitet werden. Höhe und Durchmesser des FOV hätten in den meisten Fällen kleiner gewählt werden können, liegen aber angesichts der vorhandenen Auswahl-Optionen des Röntgengeräts zur Dimensionierung der Volumina in einem akzeptablen Bereich.
We conducted a systematic review investigating the efficacy and tolerability of adrenocorticotropic hormone (ACTH) and corticosteroids in children with epilepsies other than infantile epileptic spasm syndrome (IESS) that are resistant to anti-seizure medication (ASM). We included retrospective and prospective studies reporting on more than five patients and with clear case definitions and descriptions of treatment and outcome measures. We searched multiple databases and registries, and we assessed the risk of bias in the selected studies using a questionnaire based on published templates. Results were summarized with meta-analyses that pooled logit-transformed proportions or rates. Subgroup analyses and univariable and multivariable meta-regressions were performed to examine the influence of covariates. We included 38 studies (2 controlled and 5 uncontrolled prospective; 31 retrospective) involving 1152 patients. Meta-analysis of aggregate data for the primary outcomes of seizure response and reduction of electroencephalography (EEG) spikes at the end of treatment yielded pooled proportions (PPs) of 0.60 (95% confidence interval [CI] 0.52–0.67) and 0.56 (95% CI 0.43–0.68). The relapse rate was high (PP 0.33, 95% CI 0.27–0.40). Group analyses and meta-regression showed a small benefit of ACTH and no difference between all other corticosteroids, a slightly better effect in electric status epilepticus in slow sleep (ESES) and a weaker effect in patients with cognitive impairment and “symptomatic” etiology. Obesity and Cushing's syndrome were the most common adverse effects, occurring more frequently in trials addressing continuous ACTH (PP 0.73, 95% CI 0.48–0.89) or corticosteroids (PP 0.72, 95% CI 0.54–0.85) than intermittent intravenous or oral corticosteroid administration (PP 0.05, 95% CI 0.02–0.10). The validity of these results is limited by the high risk of bias in most included studies and large heterogeneity among study results. This report was registered under International Prospective Register of Systematic Reviews (PROSPERO) number CRD42022313846. We received no financial support.
Key points
* Systematic review resulting in low to moderately solid evidence on the efficacy and tolerability of adrenocorticotropic hormone (ACTH) and corticosteroid treatment in children with epilepsy other than infantile spasms.
* Meta-analysis based on aggregate data from 2 controlled prospective, 5 uncontrolled prospective, and 31 retrospective studies.
* Pooled data showing a seizure response in 60% and electroencephalography (EEG) response in 56% of patients, with no major differences between drugs. However, 30%–40% of patients relapse after the cessation of treatment.
* The most frequent adverse effects are obesity and Cushing's syndrome, occurring in 70% of patients under continuous treatment for some weeks, but in less than 10% undergoing pulsed, intermittent regimens.
* More prospective, randomized-controlled studies are needed to improve the level of evidence and define the optimal doses and treatment duration.
In Deutschland leidet ca. jeder zehnte Mensch über 40 Jahren an einer chronischen Einschränkung seiner Nierenfunktion. Nicht wenige davon sind im Laufe der Erkrankung auf eine Nierenersatztherapie angewiesen. Die Ursachen für eine Nierenschädigung sind vielfältig. Als neuartiger und vielversprechender Therapieansatz werden aktuell Mesenchymale Stamm-/Stromazellen (MSC) als Therapeutikum für diverse Nierenerkrankungen getestet. Erste Ergebnisse klinischer Phase-I-Studien zeigen, dass MSC sicher als Immunsuppressivum nach Nierentransplantation angewendet werden können. Auch für weitere Erkrankungen der Niere sind erste klinische Studien am Laufen. MSC gelten als regenerativ, immunsupprimierend und antientzündlich. Dennoch gibt es noch einige Limitationen. Nach der Transplantation der Zellen ist das Wachstum der Zellen oft eingeschränkt und es kommt zur vermehrten Apoptose. Auch wird immer wieder ein paradoxes und entzündungsförderndes Verhalten der MSC am Wirkort beobachtet. Ein wichtiger Lösungsansatz ist eine in vitro Vorbehandlung der MSC zur Modulierung der zellulären Eigenschaften. In dieser Arbeit wurden drei Substanzen und Arzneimittel auf ihre Fähigkeit untersucht, die entzündungshemmenden Eigenschaften der MSC zu verbessern und die entzündungsfördernden zu unterdrücken. Der Fokus lag hierbei auf dem Arzneimittel Niclosamid und den beiden bisher noch nicht zugelassenen Substanzen Berberin und Gedunin, die alle in vitro und in vivo bereits erste vielversprechende antientzündliche Wirkungen bewiesen haben. Für diese Arbeit wurden MSC aus Fettgewebe isoliert (ASC) und mit LPS oder einem Cytokin-Mix (Mischung aus TNF-α, IFN-γ und IL-1β) sowie den drei Substanzen stimuliert. Untersucht wurden im Anschluss die mRNA-Expressionen der gängigsten proinflammatorischen (TNF-α, IL-6, TLR-4, ICAM-1, HLA-DR) und antiinflammatorischen Marker (IDO, IL-10), sowie mittels ELISA die Protein-Freisetzung von IL-6 und IL-8. Die vielversprechendsten Ergebnisse ließen sich durch Berberin hervorrufen. Hier zeigte sich eine deutliche Senkung der IL-8-Konzentration im ELISA. Die Anwendung des Gedunin hatte keine signifikante Wirkung auf die ASC. Niclosamid hingegen scheint widererwarten sogar entzündungsfördernd zu wirken, in dem es die IL-6-, ICAM-1-mRNA-Expression steigerte und die IDO-mRNA-Expression absenkte. Unter den drei getesteten Subtanzen hat Berberin die beste Wirkung bewiesen. Nach weiterer Testung könnte eine Anwendung mit Berberin als in vitro Präkonditionierung von MSC vielversprechend sein. Die Verwendung von Niclosamid hingegen sollte vermieden werden, die Wirkung von Gedunin müsste genauer untersucht werden.
Polygene Risikoscores (PRS) integrieren zahlreiche Einzelnukleotid-Polymorphismen (SNP) von meist geringer Effektstärke, um Auskunft über das Erkrankungsrisiko bestimmter Krankheiten zu geben. In dieser Arbeit wurde der PRS zur genetisch generalisierten Epilepsie (GGE) von Leu et al. aus dem Jahr 2019 untersucht, um festzustellen, ob über das Erkrankungsrisiko hinaus noch Korrelationen mit weiteren phänotypischen Eigenschaften von Patienten bestehen. Der Nachweis solcher Zusammenhänge würde eine Prädiktionsfähigkeit des GGE-PRS demonstrieren, die perspektivisch ein Potential für dessen klinische Anwendbarkeit, beispielsweise im Sinne der personalisierten Medizin, aufzeigen könnte.
Die Identifizierung neuer Korrelationen sollte durch Vergleich der Phänotypen von zwei Gruppen von GGE-Patienten mit extrem hohen, beziehungsweise extrem niedrigen PRS-Werten erfolgen. Hierfür wurden von 2256 Patienten aus der Datenbank von Epi25, einem internationalen Forschungskollaborativ zur Erforschung der Relevanz genetischer Faktoren bei der Entwicklung von Epilepsie, die Patienten mit den höchsten (n=59) und den niedrigsten (n=49) GGE-PRS-Werten ausgewählt. Für diese 108 Patienten wurden retrospektive klinische Daten von den jeweiligen Behandlungszentren akquiriert. Hierzu wurde den Studienleitern der Zentren ein Questionnaire mit Fragen zu zahlreichen phänotypischen Parametern der Patienten übermittelt. Die Rücklaufrate war mit 54% gut.
Die so eingeholten Patientendaten wurden anschließend mittels Exaktem Test nach Fisher und Wilcoxon-Rangsummentest statistisch analysiert, um Unterschiede zwischen den Phänotypen beider Gruppen nachzuweisen. Im Falle der Pharmakoresistenz zeichneten sich hierbei zunächst signifikante Unterschiede ab, die ein selteneres Auftreten dieser Eigenschaft für Patienten mit hohen GGE-PRS-Werten implizierten. Diese Ergebnisse waren jedoch nach einer Bonferroni-Korrektur und bei Validierung in einer größeren Kohorte (n=825) nicht mehr signifikant. Für die anderen untersuchten Parameter waren ebenfalls keine signifikanten Unterschiede nachweisbar.
Das Ergebnis, dass für keinen der untersuchten Parameter signifikante Differenzen bestanden, obwohl zwei Kohorten mit extrem gegensätzlichen PRS-Werten untersucht wurden, spricht gegen eine Verwendung des aktuell verfügbaren GGE-PRS als prädiktiver Biomarker über das Erkrankungsrisiko hinaus und somit gegen dessen klinische Anwendbarkeit. Jedoch können die nicht-signifikanten Korrelationen im Falle der Pharmakoresistenz als Hinweis verstanden werden, dass im Bereich der Pharmakotherapie Zusammenhänge zwischen Score und Phänotyp bestehen könnten, die weiterer Untersuchungen in zukünftigen Studien bedürfen. Bei Verwendung eines verbesserten GGE-PRS mit zusätzlichen risikoassoziierten SNP und verfeinerter Wichtung der Effektstärken sowie größerer Kohorten könnten in diesem Bereich möglicherweise auch signifikante Zusammenhänge nachweisbar werden.